Publications by authors named "H A de Groot-Kruseman"
Measurable residual disease (MRD) is regularly tested at later timepoints after the end of first consolidation (EOC) in children with acute lymphoblastic leukemia (ALL). The question remains whether this is useful for detecting (molecular) relapse. We investigated the clinical relevance of MRD after EOC in intermediate risk patients treated on DCOG-ALL-10 (n = 271) and DCOG-ALL-9 (n = 122), with MRD <0.
View Article and Find Full Text PDFBecause of the low mutational burden and consequently, fewer potential neoantigens, children with acute myeloid leukemia (AML) are thought to have a T cell-depleted or 'cold' tumor microenvironment and may have a low likelihood of response to T cell-directed immunotherapies. Understanding the composition, phenotype, and spatial organization of T cells and other microenvironmental populations in the pediatric AML bone marrow (BM) is essential for informing future immunotherapeutic trials about targetable immune-evasion mechanisms specific to pediatric AML. Here, we conducted a multidimensional analysis of the tumor immune microenvironment in pediatric AML and non-leukemic controls.
View Article and Find Full Text PDFInfections lead to substantial morbidity during the treatment of acute lymphoblastic leukemia (ALL) in which the adaptive immune system is severely affected, leading to declining serum immunoglobulin levels. We performed a trial to investigate whether intravenous immunoglobulin (IVIG) prophylaxis in pediatric patients with ALL could prevent admissions for fever. This randomized controlled trial was a subtrial of the national Dutch multicenter ALL study.
View Article and Find Full Text PDFArticle Synopsis
- Acute lymphoblastic leukemia (γδ T-ALL) is a rare and complex condition in children, prompting a study of 200 pediatric cases to identify its clinical and genetic characteristics.
- The research revealed that very young children (under 3 years) with γδ T-ALL face a significantly high risk and display specific genetic changes, particularly involving STAG2 inactivation and LMO2 activation.
- Importantly, their findings suggest that targeting DNA repair pathways linked to STAG2 inactivation with specific drugs could offer new treatment options and help classify patients based on their risk levels.
Article Synopsis
- Recent trials show that over 95% of kids with a specific type of leukemia called ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL) live for at least 5 years after treatment.
- Scientists looked at different drug doses and their effects on patients from various studies to see how they compare and to better understand what treatment works best.
- The results suggest that some patients could possibly receive less intensive treatment while still being treated effectively, so future research should explore the possibility of giving less medicine.